Unicycive Therapeutics Inc. (NASDAQ:UNCY)’s traded shares stood at 3.19 million during the last session. At the close of trading, the stock’s price was $2.21. The UNCY share’s 52-week high remains $2.87, putting it -29.86% down since that peak but still an impressive 81.9% since price per share fell to its 52-week low of $0.40. The company has a valuation of $25.64M, with an average of 34.0 million shares in intraday trading volume over the past 10 days and average of 5.98 million shares over the past 3 months.
Unicycive Therapeutics Inc. (NASDAQ:UNCY) trade information
Unicycive Therapeutics Inc. (UNCY) has traded red over the past five days. The stock hit a weekly high of 2.87 this Wednesday, 03/15/23. The 5-day price performance for the stock is 36.42%, and 301.82% over 30 days. With these gigs, the year-to-date price performance is 309.26%. Short interest in Unicycive Therapeutics Inc. (NASDAQ:UNCY) saw shorts transact 0.2 million shares and set a 0.29 days time to cover.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Unicycive Therapeutics Inc. (UNCY) estimates and forecasts
Looking at statistics comparing Unicycive Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Unicycive Therapeutics Inc. (UNCY) shares are 206.94% up over the last 6 months, with its year-to-date growth rate lower than industry average at -41.86% against 11.00%.
Unicycive Therapeutics Inc. has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Unicycive Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Unicycive Therapeutics Inc. (NASDAQ:UNCY)’s Major holders
Unicycive Therapeutics Inc. insiders hold 41.39% of total outstanding shares, with institutional holders owning 18.26% of the shares at 31.16% float percentage. In total, 18.26% institutions holds shares in the company, led by Nantahala Capital Management, LLC. As of Sep 29, 2022, the company held over 0.71 million shares (or 4.72% of shares), all amounting to roughly $0.42 million.
The next major institution holding the largest number of shares is Ayrton Capital LLC with 76645.0 shares, or about 0.51% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $45220.0.
We also have Fidelity NASDAQ Composite Index Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Unicycive Therapeutics Inc. (UNCY) shares. Going by data provided on Nov 29, 2022, Fidelity NASDAQ Composite Index Fund holds roughly 26109.0 shares. This is just over 0.17% of the total shares, with a market valuation of $18594.0. Data from the same date shows that the other fund manager holds a little less at 22695.0, or 0.15% of the shares, all valued at about 13390.0.